Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways

Neurochemical Research

Volumn 37, Issue 9, 2012, Pages 2033-2041

  Peltonen, I ^a   Myohanen T T ^a   Mannisto P T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Dopamine; Neurotensin; Nucleus accumbens; Prolyl endopeptidase; Prolyl oligopeptidase; Striatum

Indexed keywords

DOPAMINE; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; PROLYL ENDOPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; LIMBIC SYSTEM; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; ENZYME INHIBITORS; INJECTIONS, INTRAVENTRICULAR; LIMBIC SYSTEM; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEURAL PATHWAYS; NEUROTENSIN; OLIGOPEPTIDES; PYRAZOLES; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, NEUROTENSIN; SERINE ENDOPEPTIDASES; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

RATTUS;

EID: 84866732986     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0825-y     Document Type: Article

References (43)

1. Cunningham DF, O'Connor B (1997) Proline specific peptidases. Biochim Biophys Acta 1343:160-186
2. García-Horsman JA, Männistö PT, Venäläinen JI (2007) On the role of prolyl oligopeptidase in health and disease. Neuropeptides 41:1-24
3. Männistö PT, Venäläinen J, Jalkanen A, García-Horsman JA (2007) Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect 20:293-305
4. Jalkanen AJ, Puttonen KA, Venäläinen JI, Sinervä V, Mannila A, Ruotsalainen S, Jarho EM, Wallén EA, Männistö PT (2007) Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol 100:132-138
5. Jalkanen AJ, Savolainen K, Forsberg MM (2011) Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum. Neurosci Lett 502:107-111
6. Camargo AC, Caldo H, Emson PC (1983) Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline-endopeptidase). Biochem Biophys Res Commun 116:1151-1159
7. Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861
8. Rostene W, Brouard A, Dana C, Masuo Y, Agid F, Vial M, Lhiaubet AM, Pelaprat D (1992) Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence. Ann NY Acad Sci 668:217-231
9. Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2001) Neurotensin and dopamine interactions. Pharmacol Rev 53:453-486
10. Palacios JM, Kuhar MJ (1981) Neurotensin receptors are located on dopamine-containing neurones in rat midbrain. Nature 294:587-589
11. Nouel D, Sarret P, Vincent JP, Mazella J, Beaudet A (1999) Pharmacological, molecular and functional characterization of glial neurotensin receptors. Neuroscience 94:1189-1197
12. Trudeau LE (2000) Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors. Neuroscience 97:293-302
13. Leonetti M, Brun P, Clerget M, Steinberg R, Soubrie P, Renaud B, Suaud-Chagny MF (2004) Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice. J Neurochem 89:1-6
14. Caceda R, Kinkead B, Owens MJ, Nemeroff CB (2005) Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. J Neurosci 25:11748-11756
15. Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E (2010) Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology 58:1199-1205
16. Feifel D, Shilling PD, Melendez G (2011) Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci 125:268-272
17. St-Gelais F, Legault M, Bourque MJ, Rompre PP, Trudeau LE (2004) Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci 24: 2566-2574
18. Jomphe C, Lemelin PL, OkanoH,Kobayashi K, Trudeau LE (2006) Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons. Eur J Neurosci 24:2789-2800
19. Fawaz CS, Martel P, Leo D, Trudeau LE (2009) Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. BMC Neurosci 10:96
20. Boudin H, Pelaprat D, Rostene W, Beaudet A (1996) Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J Comp Neurol 373:76-89
21. Fassio A, Evans G, Grisshammer R, Bolam JP, Mimmack M, Emson PC (2000) Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology 39:1430-1442
22. Myöhänen TT, García-Horsman JA, Tenorio-Laranga J, Männistö PT (2009) Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem 57:831-848
23. Myöhänen TT, Venäläinen JI, Tupala E, García-Horsman JA, Miettinen R, Männistö PT (2007) Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem Res 32:1365-1374
24. Peltonen I, Myöhänen TT, Männistö PT (2011) Association of prolyl oligopeptidase with conventional neurotransmitters in the brain. CNS Neurol Disord Drug Targets 10:311-318
25. Venäläinen JI, García-Horsman JA, Forsberg MM, Jalkanen A, Wallén EA, Jarho EM, Christiaans JA, Gynther J, Männistö PT (2006) Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem Pharmacol 71:683-692
26. Jalkanen AJ, Hakkarainen JJ, Lehtonen M, Venäläinen T, Kääriäinen TM, Jarho E, Suhonen M, Forsberg MM (2011) Brain Pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the Rat. Basic Clin Pharmacol Toxicol 109:443-451
27. Jarho EM, Venäläinen JI, Huuskonen J, Christiaans JA, García- Horsman JA, Forsberg MM, Järvinen T, Gynther J, Männistö PT, Wallén EA (2004) A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem 47:5605-5607
28. Myöhänen TT, Venäläinen JI, García-Horsman JA, Piltonen M, Männistö PT (2008) Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol 507:1694-1708
29. Myöhänen TT, Venäläinen JI, García-Horsman JA, Männistö PT (2008) Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study. Neuroscience 153:1177-1189
30. Dufourny L, Warembourg M, JolivetA(1999) Quantitative studies of progesterone receptor and nitric oxide synthase colocalization with somatostatin, or neurotensin, or substance P in neurons of the guinea pig ventrolateral hypothalamic nucleus: an immunocytochemical triple-label analysis. J Chem Neuroanat 17:33-43
31. Williams FG, Beitz AJ (1989) Production and characterization of a novel monoclonal antibody against neurotensin: immunohistochemical localization in the midbrain and hypothalamus. J Histochem Cytochem 37:831-841
32. Paxinos G, Watson CD (1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego
33. Airavaara M, Mijatovic J, Vihavainen T, Piepponen TP, Saarma M, Ahtee L (2006) In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 59:321-329
34. Chang HT (1988) Substance P-dopamine relationship in the rat substantia nigra: a light and electron microscopy study of double immunocytochemically labeled materials. Brain Res 448:391-396
35. Pickel VM, Joh TH, Chan J (1988) Substance P in the rat nucleus accumbens: ultrastructural localization in axon terminals and their relation to dopaminergic afferents. Brain Res 444:247-264
36. Tamiya R, Hanada M, Kawai Y, Inagaki S, Takagi H (1990) Substance P afferents have synaptic contacts with dopaminergic neurons in the ventral tegmental area of the rat. Neurosci Lett 110:11-15
37. Mendez I, Elisevich K, Flumerfelt B (1992) Substance P synaptic interactions with GABAergic and dopaminergic neurons in rat substantia nigra: an ultrastructural double-labeling immunocytochemical study. Brain Res Bull 28:557-563
38. Barnes JM, Barnes NM, Costall B, Cox AJ, Domeney AM, Kelly ME, Naylor RJ (1990) Neurochemical consequences following injection of the substance P analogue, DiMe-C7, into the rat ventral tegmental area. Pharmacol Biochem Behav 37:839-841
39. Boix F, Mattioli R, Adams F, Huston JP, Schwarting RK (1992) Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens. Eur J Pharmacol 216:103-107
40. Mertens B, Vanderheyden P, Michotte Y, Sarre S (2010) The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst 11:49-56
41. Brown DC, Steward LJ, Ge J, Barnes NM (1996) Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 118:414-420
42. Schulz I, Zeitschel U, Rudolph T, Ruiz-Carrillo D, Rahfeld JU, Gerhartz B, Bigl V, Demuth HU, Rossner S (2005) Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 94:970-979
43. Jalkanen AJ, Piepponen TP, Hakkarainen JJ, De Meester I, Lambeir AM, Forsberg MM (2012) The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum. Neurochem Int 60:301-309